SAGE Earnings Prediction
The chart below shows how SAGE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SAGE sees a +18.66% change in stock price 10 days leading up to the earnings, and a -5.41% change 10 days following the report. On the earnings day itself, the stock moves by -5.61%. This data can give you a slight idea of what to expect for the next quarter's release.
SAGE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.87M
337.08%
37.17%
Gross Margin
55.54%
-16.71%
-33.68%
Operating Margin
-852.51%
-87.01%
-33.71%
Net Margin
-788.06%
-89.38%
-33.69%
EPS
-1.53
-54.60%
-10.00%
No Data Available
SAGE Earnings Analysis
Sage Therapeutics, Inc Corporation (SAGE.O) Earnings Conference Call
Positive
Collaboration Revenue Growth: ZURZUVAE generated $22.1 million in total revenue in the third quarter of 2024, of which Sage recognized $11 million in collaboration revenue, representing a 49% growth in revenue over the second quarter.
PPD Prescription Growth: Increased demand was observed as measured by shipments in the third quarter, with approximately 2,000 prescriptions filled and delivered to women with PPD, representing an approximately 40% growth compared to the second quarter.
Strong Financial Foundation: Sage ended the third quarter of 2024 with cash, cash equivalents, and marketable securities of approximately $569 million, providing a strong financial foundation for future growth.
Restructuring for Future Success: Sage's restructuring is expected to right-size the company for future success, enhancing its operational efficiency and focus on key therapeutic areas.
Women’s Health Progress: The company is making notable progress in supporting more women with PPD since the launch of ZURZUVAE, indicating a positive trajectory in patient treatment and engagement.
Negative
Collaboration Revenue Growth: ZURZUVAE generated $22.1 million in total revenue in the third quarter of 2024, of which Sage recognized $11 million in collaboration revenue, representing a 49% growth in revenue over the second quarter.
R&D and SG&A Expenses: R&D expenses were $54.6 million in the third quarter of 2024, while SG&A expenses were $53.2 million in the same period.
Net Loss Analysis: Our net loss for the third quarter of 2024 was $93.6 million, indicating significant financial strain.
Cash Management Improvement Needed: We ended the third quarter of 2024 with cash, cash equivalents, and marketable securities of approximately $569 million, reflecting a need for better cash management.
Business Reorganization Announcement: We announced earlier this month that we are implementing a reorganization of our business operations intended to strengthen our balance sheet and focus investment to support the ongoing launch of ZURZUVAE.
SAGE FAQs
How does SAGE typically perform around its earnings report dates?
Is Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SAGE Earning Call Sentiment
Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SAGE.O
0.4%Positive
The earnings call presents mixed signals. Strong revenue growth (49% QoQ) and decreasing operating expenses are positive, but financial losses and pipeline setbacks, including termination of key collaborations, raise concerns. Management's avoidance of guidance and lack of shareholder return plan further tempers enthusiasm. Overall, the sentiment is neutral due to balanced positives and negatives.
